These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 9085149)
1. The intermediate filament peripherin is expressed in cutaneous melanocytic lesions. Prieto VG; McNutt NS; Lugo J; Reed JA J Cutan Pathol; 1997 Mar; 24(3):145-50. PubMed ID: 9085149 [TBL] [Abstract][Full Text] [Related]
2. Differential expression of the intermediate filament peripherin in cutaneous neural lesions and neurotized melanocytic nevi. Prieto VG; McNutt NS; Lugo J; Reed JA Am J Surg Pathol; 1997 Dec; 21(12):1450-4. PubMed ID: 9414188 [TBL] [Abstract][Full Text] [Related]
3. Expression of the intermediate filament peripherin in skin tumors. Kanitakis J; Bourchany D; Faure M; Claudy A Eur J Dermatol; 1998; 8(5):339-42. PubMed ID: 9683874 [TBL] [Abstract][Full Text] [Related]
4. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions. Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299 [TBL] [Abstract][Full Text] [Related]
5. Neurotized nevi of the oral mucosa: an immunohistochemical and ultrastructural analysis of nevic corpuscles. Ide F; Mishima K; Yamada H; Saito I; Tanaka A; Kusama K J Oral Pathol Med; 2007 Sep; 36(8):505-10. PubMed ID: 17686011 [TBL] [Abstract][Full Text] [Related]
6. Expression of the proliferation and apoptosis-associated CAS protein in benign and malignant cutaneous melanocytic lesions. Böni R; Wellmann A; Man YG; Hofbauer G; Brinkmann U Am J Dermatopathol; 1999 Apr; 21(2):125-8. PubMed ID: 10218671 [TBL] [Abstract][Full Text] [Related]
7. The neuropeptide/mast cell secretagogue substance P is expressed in cutaneous melanocytic lesions. Khare VK; Albino AP; Reed JA J Cutan Pathol; 1998 Jan; 25(1):2-10. PubMed ID: 9508337 [TBL] [Abstract][Full Text] [Related]
8. Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma. Fang D; Hallman J; Sangha N; Kute TE; Hammarback JA; White WL; Setaluri V Am J Pathol; 2001 Jun; 158(6):2107-15. PubMed ID: 11395388 [TBL] [Abstract][Full Text] [Related]
9. Nevoid melanoma: a clinicopathological study of seven cases of malignant melanoma mimicking spindle and epithelioid cell nevus and verrucous dermal nevus. Wong TY; Suster S; Duncan LM; Mihm MC Hum Pathol; 1995 Feb; 26(2):171-9. PubMed ID: 7860047 [TBL] [Abstract][Full Text] [Related]
10. [Unusual and unknown aspect of cutaneous malignant melanoma: minimal deviation malignant melanoma. Retrospective study of 45 cases]. Mérot Y; Mihm MC Ann Dermatol Venereol; 1985; 112(4):325-36. PubMed ID: 4026131 [TBL] [Abstract][Full Text] [Related]
12. Topography of Protein Kinase C βII in Benign and Malignant Melanocytic Lesions. Krasagakis K; Tsentelierou E; Chlouverakis G; Stathopoulos EN Int J Surg Pathol; 2017 Sep; 25(6):497-501. PubMed ID: 28436290 [TBL] [Abstract][Full Text] [Related]
13. [Epithelioid and hyperpigmented melanocytic tumors. An overview]. Kutzner H; Schärer L; Requena L Pathologe; 2007 Nov; 28(6):411-21. PubMed ID: 17899087 [TBL] [Abstract][Full Text] [Related]
14. Melanocytic lesions associated with dermatofibromas: a spectrum of lesions ranging from junctional nevus to malignant melanoma in situ. King R; Googe PB; Page RN; Mihm MC Mod Pathol; 2005 Aug; 18(8):1043-7. PubMed ID: 15803191 [TBL] [Abstract][Full Text] [Related]
15. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Sparrow LE; Eldon MJ; English DR; Heenan PJ Am J Dermatopathol; 1998 Jun; 20(3):255-61. PubMed ID: 9650698 [TBL] [Abstract][Full Text] [Related]
16. Acral melanocytic neoplasms: a histologic analysis of 158 lesions. Boyd AS; Rapini RP J Am Acad Dermatol; 1994 Nov; 31(5 Pt 1):740-5. PubMed ID: 7929919 [TBL] [Abstract][Full Text] [Related]
17. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma. Isabel Zhu Y; Fitzpatrick JE J Cutan Pathol; 2006 Jan; 33(1):33-7. PubMed ID: 16441409 [TBL] [Abstract][Full Text] [Related]
18. Meyerson Phenomenon as a Component of Melanoma in situ. Sezer E; Özturk Durmaz E; Çetin E; Şahin S Acta Dermatovenerol Croat; 2016 Apr; 24(1):81-2. PubMed ID: 27149137 [TBL] [Abstract][Full Text] [Related]
19. The initial steps of tumor progression in melanocytic lineage: a histochemical approach. Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897 [TBL] [Abstract][Full Text] [Related]
20. Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression. Reed JA; McNutt NS; Bogdany JK; Albino AP J Cutan Pathol; 1996 Dec; 23(6):495-505. PubMed ID: 9001979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]